



## Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference

June 9, 2022

LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 9, 2022-- [Concert Pharmaceuticals, Inc.](#) (NASDAQ: CNCE) today announced that it will participate in a fireside chat at The JMP Securities Life Sciences Conference on June 16, 2022 at 1:00 p.m. ET in New York, NY.

A webcast of the JMP fireside chat may be accessed in the [Investors](#) section of the Company's website at [www.concertpharma.com](http://www.concertpharma.com). A replay of the webcast will be available on Concert's website for two weeks following the presentation.

### About Concert

[Concert Pharmaceuticals](#) is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its [DCE Platform](#)<sup>®</sup> (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead [product candidate](#) is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit [www.concertpharma.com](http://www.concertpharma.com) or follow us on Twitter at [@ConcertPharma](#) or on [LinkedIn](#).

View source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20220609005071/en/>

Justine Koenigsberg  
(781) 674-5284  
[ir@concertpharma.com](mailto:ir@concertpharma.com)

Source: Concert Pharmaceuticals, Inc.